114 related articles for article (PubMed ID: 27631463)
1. Cetuximab Pharmacokinetics Influences Overall Survival in Patients With Head and Neck Cancer.
Pointreau Y; Azzopardi N; Ternant D; Calais G; Paintaud G
Ther Drug Monit; 2016 Oct; 38(5):567-72. PubMed ID: 27631463
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.
Azzopardi N; Lecomte T; Ternant D; Boisdron-Celle M; Piller F; Morel A; Gouilleux-Gruart V; Vignault-Desvignes C; Watier H; Gamelin E; Paintaud G
Clin Cancer Res; 2011 Oct; 17(19):6329-37. PubMed ID: 21953502
[TBL] [Abstract][Full Text] [Related]
3. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck.
Dirks NL; Nolting A; Kovar A; Meibohm B
J Clin Pharmacol; 2008 Mar; 48(3):267-78. PubMed ID: 18218786
[TBL] [Abstract][Full Text] [Related]
5. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Le Louedec F; Alix-Panabières C; Lafont T; Allal BC; Garrel R; Digue L; Guigay J; Cupissol D; Delord JP; Lallemant B; Alfonsi M; Aubry K; Mazel M; Becher F; Perriard F; Chatelut E; Thomas F
Br J Clin Pharmacol; 2019 Jun; 85(6):1357-1366. PubMed ID: 30811063
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.
Tiwari S; Goel V; John MC; Patnaik N; Doval DC
Indian J Cancer; 2016; 53(4):487-492. PubMed ID: 28485336
[TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
[TBL] [Abstract][Full Text] [Related]
9. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.
Bossi P; Kornek G; Lanzetta G; Rozzi A; Füreder T; Locati L; Licitra L
Head Neck; 2013 Oct; 35(10):1471-4. PubMed ID: 23042567
[TBL] [Abstract][Full Text] [Related]
10. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U
Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686
[TBL] [Abstract][Full Text] [Related]
11. Afatinib in squamous cell carcinoma of the head and neck.
Specenier P; Vermorken J
Expert Opin Pharmacother; 2016 Jun; 17(9):1295-301. PubMed ID: 27160335
[TBL] [Abstract][Full Text] [Related]
12. Impact of prophylactic percutaneous endoscopic gastrostomy tube placement on treatment tolerance in head and neck cancer patients treated with cetuximab plus radiation.
Yamazaki T; Enokida T; Wakasugi T; Zenda S; Motegi A; Arahira S; Akimoto T; Tahara M
Jpn J Clin Oncol; 2016 Sep; 46(9):825-31. PubMed ID: 27317736
[TBL] [Abstract][Full Text] [Related]
13. Intravenous 5-Fluorouracil in Patients With Advanced Squamous Cell Carcinoma: A Retrospective Study.
Buxó E; Sosa A; Reig O; Victoria I; Caballero M; Grau JJ; Garcia-Morillo M
Ann Otol Rhinol Laryngol; 2018 Jul; 127(7):456-462. PubMed ID: 29852745
[TBL] [Abstract][Full Text] [Related]
14. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.
Mehra R; Cohen RB; Burtness BA
Clin Adv Hematol Oncol; 2008 Oct; 6(10):742-50. PubMed ID: 18997665
[TBL] [Abstract][Full Text] [Related]
15. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma.
De Felice F; Vetrone L; Bulzonetti N; Caiazzo R; Marampon F; Musio D; Tombolini V
Med Oncol; 2019 Jun; 36(8):68. PubMed ID: 31190132
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J; Bishop J; Sidransky D; Ravi R; Bedi A; Chung CH
Oral Oncol; 2015 Apr; 51(4):376-82. PubMed ID: 25593015
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular.
Chang PM; Hsieh YY; Chen MH; Tzeng CH; Chu PY; Chang SY; Chen PM; Yang MH
J Chin Med Assoc; 2010 Jun; 73(6):292-9. PubMed ID: 20603086
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma.
Fury MG; Xiao H; Sherman EJ; Baxi S; Smith-Marrone S; Schupak K; Gewanter R; Gelblum D; Haque S; Schoder H; Shah JP; Katabi N; Kurtzman R; Lipson B; Cox L; Lee NY; Pfister DG
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E566-70. PubMed ID: 25784616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]